| A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable A Cortellini, M Bersanelli, S Buti, K Cannita, D Santini, F Perrone, R Giusti, ... Journal for immunotherapy of cancer 7, 1-11, 2019 | 351 | 2019 |
| Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional … B Ricciuti, C Genova, A De Giglio, M Bassanelli, MG Dal Bello, G Metro, ... Journal of cancer research and clinical oncology 145, 479-485, 2019 | 307 | 2019 |
| Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis H Abu-Sbeih, FS Ali, AR Naqash, DH Owen, S Patel, GA Otterson, ... Journal of clinical oncology 37 (30), 2738-2745, 2019 | 174 | 2019 |
| Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the … E Verzoni, G Cartenì, E Cortesi, D Giannarelli, A De Giglio, R Sabbatini, ... Journal for immunotherapy of cancer 7, 1-9, 2019 | 131 | 2019 |
| Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/Programmed cell death … A Cortellini, M Bersanelli, D Santini, S Buti, M Tiseo, K Cannita, F Perrone, ... European Journal of Cancer 128, 17-26, 2020 | 98 | 2020 |
| Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials A Di Federico, A Rizzo, R Carloni, A De Giglio, R Bruno, D Ricci, G Brandi Expert Opinion on Investigational Drugs 31 (4), 361-369, 2022 | 88 | 2022 |
| Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort AR Naqash, B Ricciuti, DH Owen, V Florou, Y Toi, C Cherry, M Hafiz, ... Cancer Immunology, Immunotherapy 69, 1177-1187, 2020 | 79 | 2020 |
| STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive? A Di Federico, A De Giglio, C Parisi, F Gelsomino European Journal of Cancer 157, 108-113, 2021 | 67 | 2021 |
| The landscape of immunotherapy in advanced NSCLC: Driving beyond PD-1/PD-L1 inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, vaccines) A De Giglio, A Di Federico, G Nuvola, C Deiana, F Gelsomino Current oncology reports 23, 1-15, 2021 | 59 | 2021 |
| Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: a multicentre study O Nigro, G Pinotti, F De Galitiis, FR Di Pietro, R Giusti, M Filetti, ... European Journal of Cancer 134, 19-28, 2020 | 58 | 2020 |
| Immunotherapy in pancreatic cancer: why do we keep failing? A focus on tumor immune microenvironment, predictive biomarkers and treatment outcomes A Di Federico, M Mosca, R Pagani, R Carloni, G Frega, A De Giglio, ... Cancers 14 (10), 2429, 2022 | 51 | 2022 |
| The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1≥ 50% advanced non-small-cell lung cancer GL Banna, A Cortellini, DL Cortinovis, M Tiseo, J Aerts, F Barbieri, ... Esmo Open 6 (2), 100078, 2021 | 49 | 2021 |
| Impact of intercurrent introduction of steroids on clinical outcomes in advanced non-small-cell lung cancer (NSCLC) patients under immune-checkpoint inhibitors (ICI) A De Giglio, L Mezquita, E Auclin, F Blanc-Durand, M Riudavets, ... Cancers 12 (10), 2827, 2020 | 49 | 2020 |
| Safety and efficacy of nivolumab in patients with advanced Non–small-cell lung cancer treated beyond progression B Ricciuti, C Genova, M Bassanelli, A De Giglio, M Brambilla, G Metro, ... Clinical Lung Cancer 20 (3), 178-185. e2, 2019 | 48 | 2019 |
| PD-L1 expression in circulating tumor cells as a promising prognostic biomarker in advanced non–small-cell lung cancer treated with immune checkpoint inhibitors FG Dall'Olio, F Gelsomino, N Conci, L Marcolin, A De Giglio, G Grilli, ... Clinical Lung Cancer 22 (5), 423-431, 2021 | 46 | 2021 |
| Smoking status during first‐line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study A Cortellini, A De Giglio, K Cannita, DL Cortinovis, R Cornelissen, ... Thoracic Cancer 12 (6), 880-889, 2021 | 44 | 2021 |
| Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations M Riudavets, E Auclin, M Mosteiro, N Dempsey, M Majem, R Lobefaro, ... European Journal of Cancer 167, 142-148, 2022 | 38 | 2022 |
| Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy B Ricciuti, S Baglivo, L Paglialunga, A De Giglio, G Bellezza, R Chiari, ... Therapeutic advances in medical oncology 9 (6), 387-404, 2017 | 38 | 2017 |
| Comparison of sequential testing and next generation sequencing in advanced lung adenocarcinoma patients–a single centre experience FG Dall’Olio, N Conci, G Rossi, M Fiorentino, A De Giglio, G Grilli, ... Lung Cancer 149, 5-9, 2020 | 35 | 2020 |
| Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience B Ricciuti, S Baglivo, A De Giglio, R Chiari Therapeutic advances in respiratory disease 12, 1753466618808659, 2018 | 29 | 2018 |
